China's new coronavirus therapeutic antibody drug is approved for emergency use in Europe and the United States

Beijing BEIJING, March 15 (Reporter Sun Zifa) reporter on the 15th from China Kexue Yuan Institute of Microbiology was informed that a new crown therapeutic antibody drug and combination therapy by the firm and the king of real biological joint research and development, following the February After the United States obtained emergency use authorization, it was recently approved for emergency use in the European Union.

Zhong Keyuan microbial earlier, the European Medicines Agency with a human medicinal products committee would allow EU member states recently, the use of combination therapy with monoclonal antibodies LY-CoV555 LY-CoV016's ( "antibody cocktail" therapy) In a public health emergency respond to the new crown pneumonia infection, which, LY-CoV016 by the Zhong Keyuan the joint research and development of microorganisms and the king of real creatures.

Previously, the U.

According to the Keyuan microorganisms introduced specific monoclonal neutralizing antibodies known to target new virus crown "biological missile", the new crown pneumonia has both prevention and treatment, as early as the beginning of a new outbreak of the epidemic crown, in Keyuan microorganisms on Start to deploy monoclonal antibody research and development, use the single B-cell antibody screening platform to isolate and screen multiple antibodies from patients in convalescence, and efficiently cooperate with enterprises to rapidly develop multiple parallel development and large-scale production of candidate antibodies.

March 2020, Zhong Keyuan microorganisms will develop successful new crown therapeutic antibody drug JS016 (ie LY-CoV016) business development grant Jun real life.

In June 2020, LY-JS016 (that is, LY-CoV016) obtained the clinical trial license from the China National Medical Products Administration and the U.

In October 2020, Eli Lilly Pharmaceuticals disclosed the interim data of a phase II clinical trial of a combination therapy of LY-CoV555 and LY-CoV016, which showed that when the trial reached the primary and secondary endpoints, the drug significantly reduced the virus titer and improved Clinical symptoms.

Zhong Keyuan microorganisms, said the US and Europe have approved the combination therapy new crown therapeutic antibody drug developed by Chinese emergency use, marking a new crown with a virus-specific antibodies Chinese independent intellectual property rights of drug safety and efficacy has been recognized around the world.